Oct. 28, 2021 – “Fluvoxamine may reduce the production of inflammatory molecules called cytokines, that can be triggered by SARS-CoV-2 infection,” Reiersen said in a statement. The drug may also reduce blood platelets, which may affect the clotting effects of coronavirus infection. Reierson and colleagues gave 741 volunteers with Covid-19 100 mg of fluvoxamine twice a day for 10 days while 756 volunteers got a placebo.
Among the patients who got fluvoxamine, 79 — or about 11% — needed treatment in an ER or hospital room compared to nearly 16% of those given placebos. It was a 5% decrease in absolute risk and a 32% decrease in relative risk.
EMR MATTERS – October 2024 - The challenge is that many in the behavioral health…
TOO LITTLE, TOO LATE? – Dec. 19, 2024 - Assembly Bill 56 (AB 56) proposes…
AND STOPPED DIGGING – Dec. 4, 2024 - In a new interview with The Times,…
NOT JUST IN PENCILS – Dec. 8, 2024 - Americans born before 1966 experienced “significantly…
AS SUCCESSFUL AS EVER – Dec. 3, 2024 - Family Affair actor Johnny Whitaker looked…
ALANON Plus – Dec. 7, 2024 - A high percentage of treatment failures occur due…